InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（5 笔）
内部人交易记录
首席财务官已披露买入
2
已披露卖出
5
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Soni Manmeet Singh, 首席财务官. Director active across 2 companies, notably Reata Pharmaceuticals INC. In total, 15 disclosures have been logged. Breakdown: 2 buys · 5 sells. Total volume traded: €7.1m. History available since 31 December 2021. The latest transaction was disclosed on 21 October 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Soni Manmeet Singh
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报15 总计
53,361 股@ US$18.7413.2% 占其流量Common StockSEC:0001569769-25-000002:0
44,052 股@ US$22.7016.1% 占其流量Common StockSEC:0001599298-24-000136:0
2,976,190 股@ US$1.6883.9% 占其流量Common StockSEC:0001569769-23-000007:0
标准退出：2024年1月11日 (T+90)
62,621 股Class A common stockSEC:0000899243-23-019540:0
1,755 股@ US$168.41359.8% 占其流量Class A common stockSEC:0001209191-23-046306:0
75,000 股Class A common stockSEC:0001209191-23-044009:0
6,000 股0Class A common stockSEC:0001209191-23-041931:0
4,711 股@ US$99.617315.8% 占其流量Class A common stockSEC:0001209191-23-037043:0
12,440 股@ US$84.320134.9% 占其流量Class A common stockSEC:0001209191-23-030223:0
50,000 股0Class A common stockSEC:0001209191-23-028269:0
622 股@ US$84.6951.8% 占其流量Class A common stockSEC:0001209191-23-017235:0
3,587 股@ US$87.9710.8% 占其流量Class A common stockSEC:0001209191-23-016339:0
23,513 股0Class A common stockSEC:0001209191-23-001143:0
50,000 股0Class A common stockSEC:0001209191-22-001633:0
16,000 股@ US$26.222815.5% 占其流量Class A common stockSEC:0001209191-22-000391:0
标准退出：2022年3月31日 (T+90)
15 条申报中的 15 条
About Soni Manmeet Singh
Soni Manmeet Singh is Chief Operating Officer and Chief Financial Officer, with 15 filings in total. Across the 15 sampled filings, purchases amount to EUR 5115775 and sales to EUR 2019458, with filings spanning from 2022-01-04 to 2025-10-23. The filings concern Reata Pharmaceuticals INC and Summit Therapeutics Inc., and the modal transaction nature is Attribution.
